良性前列腺增生的药物治疗(6)
12. Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-death protease. Nature, 1997,388:300-304.
13. Marcelli M, Cunningham GR, Walkup M, et al. Signal pathway activated during apoptosis of the prostate cancer cell line LNCaP：Over expression of Caspase 7 as a new gene therapy for prostate can-cer. Cancer Res,1999,59:382-390.
14. Weingartner K, Ben Sasson SA, Stewart R, et al. Endothelial cell proliferation activity in BPH and prostate cancer, an in vitro model for assessment. J Urol,1998,159:465-470.
, 百拇医药
15. Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology,1998,139:441-442.
16. Nelson NJ. Angiogenesis research is on fast forward. J Natl Cancer Inst, 1999,91:820-822.
17. Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia：an unknown feature of acronegaly. J Clin Endocrinol Metab, 1998,83:775-779.
18. Coffey DS. Controversies in the manage-ment of lowr urinary tract symptoms：an overview.Br J Urol, 1998,81(Supple 1):1-5.
, 百拇医药
19. Price DT. New concepts in alpha receptor biology. Office Education of 94th Annual Meeting, AUA,1999.
20. Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosis apoptosis by doxazosin in benign prostatic hyperplasia. J Urol,1998,159:1810-1815.
21. Fukasawa R, Tahiguchi N, Moriyama N, et al. The alpha IL-adrenoceptor subtype im the lower urinary tract：a comparison of human urethra and prostate. Br J Urol,1998,82:733-737.
, 百拇医药
22. Kawabe K.Current status of research on prostate-selective α-antagonists. Br J Urol, 1998,81(Suppl 1):48-50.
23. Clarke DE .Alpha adrenoreceptor blockade in the treatment of BPH past, present and future. Br J Urol,1998,82:107.
24. Kaplan SA. Medical therapy in the manage-ment of BPH. Progression versus symptoms. Office Education of 94th Annual Meeting AUA,1999.
25. Lepor H, Williford WO, Barry MJ,et al.The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Eng1 J Med, 1996,335:533-539.
, 百拇医药
26. Hudson PB, Boake R, Trachtenberh J, et al. Efficiency of finasteride is maintained in patients with BPH treated for 5 years. Urology,1999,53:690-695.
27. Mc Connell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long Term Efficacy and Safety Study Group.N Eng1 J Med, 1998,338:557-563., 百拇医药(鲍镇美)
13. Marcelli M, Cunningham GR, Walkup M, et al. Signal pathway activated during apoptosis of the prostate cancer cell line LNCaP：Over expression of Caspase 7 as a new gene therapy for prostate can-cer. Cancer Res,1999,59:382-390.
14. Weingartner K, Ben Sasson SA, Stewart R, et al. Endothelial cell proliferation activity in BPH and prostate cancer, an in vitro model for assessment. J Urol,1998,159:465-470.
, 百拇医药
15. Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology,1998,139:441-442.
16. Nelson NJ. Angiogenesis research is on fast forward. J Natl Cancer Inst, 1999,91:820-822.
17. Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia：an unknown feature of acronegaly. J Clin Endocrinol Metab, 1998,83:775-779.
18. Coffey DS. Controversies in the manage-ment of lowr urinary tract symptoms：an overview.Br J Urol, 1998,81(Supple 1):1-5.
, 百拇医药
19. Price DT. New concepts in alpha receptor biology. Office Education of 94th Annual Meeting, AUA,1999.
20. Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosis apoptosis by doxazosin in benign prostatic hyperplasia. J Urol,1998,159:1810-1815.
21. Fukasawa R, Tahiguchi N, Moriyama N, et al. The alpha IL-adrenoceptor subtype im the lower urinary tract：a comparison of human urethra and prostate. Br J Urol,1998,82:733-737.
, 百拇医药
22. Kawabe K.Current status of research on prostate-selective α-antagonists. Br J Urol, 1998,81(Suppl 1):48-50.
23. Clarke DE .Alpha adrenoreceptor blockade in the treatment of BPH past, present and future. Br J Urol,1998,82:107.
24. Kaplan SA. Medical therapy in the manage-ment of BPH. Progression versus symptoms. Office Education of 94th Annual Meeting AUA,1999.
25. Lepor H, Williford WO, Barry MJ,et al.The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Eng1 J Med, 1996,335:533-539.
, 百拇医药
26. Hudson PB, Boake R, Trachtenberh J, et al. Efficiency of finasteride is maintained in patients with BPH treated for 5 years. Urology,1999,53:690-695.
27. Mc Connell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long Term Efficacy and Safety Study Group.N Eng1 J Med, 1998,338:557-563., 百拇医药(鲍镇美)